PE110298A1 - Dihidrato d de olanzapina - Google Patents
Dihidrato d de olanzapinaInfo
- Publication number
- PE110298A1 PE110298A1 PE1997000853A PE00085397A PE110298A1 PE 110298 A1 PE110298 A1 PE 110298A1 PE 1997000853 A PE1997000853 A PE 1997000853A PE 00085397 A PE00085397 A PE 00085397A PE 110298 A1 PE110298 A1 PE 110298A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- olanzapine
- olanzapine dihydrate
- dihydrate
- piperacinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
CARACTERIZADO POR EL SIGUIENTE PATRON DE DIFRACCION DE POLVO CON RAYOS X, EXPRESADO EN ESPACIOS INTERPLANARES (d): 9,4511 7,7098 7,4482 6,9807 6,5252 5,7076 5,5539 5,223 4,9803 4,8908 4,784 4,6947 4,4271 4,3956 4,3492 4,2834 4,1156 3,7837 3,7118 3,5757 3,482 3,3758 3,3274 3,2413 3,1879 3,135 3,0979 3,016 2,9637 2,907 2,8256 2,7914 2,7317 2,6732 2,5863. EL DIHIDRATO "D" CRISTALINO DE 2-METIL-4-(4-METIL-1-PIPERACINIL)-1OH-TIENO[2,3-b][1,5]BENZODIAZEPINA (OLANZAPINA) ES SOLIDO Y ESTABLE, Y ES USADO EN FORMULACIONES ACUOSAS PARA EL TRATAMIENTO DE LA ANSIEDAD, ESQUIZOFRENIA, DESORDENES INTESTINALES FUNCIONALES Y PSICOSIS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2648696P | 1996-09-23 | 1996-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE110298A1 true PE110298A1 (es) | 1999-01-18 |
Family
ID=21832112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1997000853A PE110298A1 (es) | 1996-09-23 | 1997-09-23 | Dihidrato d de olanzapina |
Country Status (35)
Country | Link |
---|---|
US (1) | US6251895B1 (es) |
EP (1) | EP0831097B1 (es) |
JP (1) | JP2001500878A (es) |
KR (1) | KR100516088B1 (es) |
CN (1) | CN1146567C (es) |
AR (1) | AR009801A1 (es) |
AT (1) | ATE221074T1 (es) |
AU (1) | AU720366B2 (es) |
BR (1) | BR9711541A (es) |
CA (1) | CA2266444C (es) |
CO (1) | CO4900057A1 (es) |
CZ (1) | CZ299247B6 (es) |
DE (1) | DE69714165T2 (es) |
DK (1) | DK0831097T3 (es) |
EA (1) | EA001881B1 (es) |
EG (1) | EG23815A (es) |
ES (1) | ES2180899T3 (es) |
HK (1) | HK1009809A1 (es) |
HU (1) | HU226167B1 (es) |
ID (1) | ID21924A (es) |
IL (1) | IL128956A0 (es) |
MY (1) | MY125467A (es) |
NO (1) | NO323979B1 (es) |
NZ (1) | NZ334346A (es) |
PE (1) | PE110298A1 (es) |
PL (1) | PL194074B1 (es) |
PT (1) | PT831097E (es) |
RS (1) | RS49597B (es) |
SI (1) | SI0831097T1 (es) |
SV (1) | SV1997000079A (es) |
TR (1) | TR199900639T2 (es) |
TW (1) | TW518335B (es) |
UA (1) | UA56184C2 (es) |
WO (1) | WO1998011893A1 (es) |
ZA (1) | ZA978512B (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA978515B (en) * | 1996-09-23 | 1999-03-23 | Lilly Co Eli | Intermediates and process for preparing olanzapine |
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
CA2344873A1 (en) * | 1998-09-30 | 2000-04-06 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
PT1246827E (pt) * | 1999-12-28 | 2005-08-31 | Cipla Ltd | Novas formas polimerficas da olanzapina |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
WO2002018390A1 (en) * | 2000-08-31 | 2002-03-07 | Dr. Reddy's Laboratories Ltd. | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
AU2002340328A1 (en) * | 2001-10-29 | 2003-05-12 | Janet I. Cord | Olanzapine dihydrate-ii a process for its preparation and use thereof |
SI1513846T1 (sl) * | 2002-05-31 | 2011-11-30 | Sandoz Ag | Postopek za pripravo olanzapina form I |
SI21270A (sl) | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
EP1575962A1 (en) * | 2002-12-24 | 2005-09-21 | Teva Pharmaceutical Industries Limited | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
EP1709053B1 (en) | 2004-01-27 | 2011-04-06 | Synthon B.V. | Stable salts of olanzapine |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
DE05783995T1 (de) * | 2004-07-14 | 2007-10-11 | Shasun Chemicals and Drugs Ltd., Chennai | Verbessertes verfahren zur herstellung von form i aus olanzapin |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
US7829700B2 (en) | 2004-09-06 | 2010-11-09 | Shasun Chemicals And Drugs Limited | Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine |
UA91520C2 (en) | 2004-09-29 | 2010-08-10 | Баер Шеринг Фарма Акциенгезельшафт | Thermodynamically stable form of tosylate |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
SI1838716T1 (sl) | 2005-01-05 | 2011-10-28 | Lilly Co Eli | Olanzapin pamoat dihidrat |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US8551986B2 (en) * | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
US7834176B2 (en) * | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
NZ619413A (en) | 2006-05-04 | 2015-08-28 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
EP2185559A1 (en) | 2007-08-03 | 2010-05-19 | Boehringer Ingelheim International GmbH | Crystalline form of a dihydropteridione derivative |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
WO2010011232A1 (en) * | 2008-07-24 | 2010-01-28 | Handa Pharmaceuticals, Llc | Stabilized atypical antipsychotic formulation |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
RU2011113823A (ru) | 2008-09-10 | 2012-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療 |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
JP2016027003A (ja) * | 2012-11-20 | 2016-02-18 | 大蔵製薬株式会社 | 長期間安定なオランザピンの水性医薬製剤 |
WO2015011236A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5302716A (en) * | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
DE69329887T2 (de) * | 1992-05-29 | 2001-05-23 | Lilly Co Eli | Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems |
MX9606595A (es) | 1994-06-28 | 1997-05-31 | Grace W R & Co | Bolsa que tiene parches protectores. |
US5631250A (en) * | 1995-03-24 | 1997-05-20 | Eli Lilly And Company | Process and solvate of 2-methyl-thieno-benzodiazepine |
IL117612A0 (en) * | 1995-03-24 | 1996-07-23 | Lilly Co Eli | Granule formulation for olanzapine |
EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
EG24221A (en) * | 1995-03-24 | 2008-11-10 | Lilly Co Eli | Process for preparing olanzapine |
-
1997
- 1997-09-18 AU AU44241/97A patent/AU720366B2/en not_active Ceased
- 1997-09-18 NZ NZ334346A patent/NZ334346A/en not_active IP Right Cessation
- 1997-09-18 KR KR10-1999-7002423A patent/KR100516088B1/ko not_active IP Right Cessation
- 1997-09-18 CZ CZ0098999A patent/CZ299247B6/cs not_active IP Right Cessation
- 1997-09-18 IL IL12895697A patent/IL128956A0/xx not_active IP Right Cessation
- 1997-09-18 HU HU0000065A patent/HU226167B1/hu not_active IP Right Cessation
- 1997-09-18 TR TR1999/00639T patent/TR199900639T2/xx unknown
- 1997-09-18 PL PL97332541A patent/PL194074B1/pl unknown
- 1997-09-18 UA UA99031634A patent/UA56184C2/uk unknown
- 1997-09-18 RS YUP-154/99A patent/RS49597B/sr unknown
- 1997-09-18 ID IDW990059A patent/ID21924A/id unknown
- 1997-09-18 CN CNB971981213A patent/CN1146567C/zh not_active Expired - Fee Related
- 1997-09-18 JP JP10514881A patent/JP2001500878A/ja not_active Withdrawn
- 1997-09-18 EA EA199900325A patent/EA001881B1/ru not_active IP Right Cessation
- 1997-09-18 WO PCT/US1997/016586 patent/WO1998011893A1/en not_active Application Discontinuation
- 1997-09-18 BR BR9711541A patent/BR9711541A/pt not_active IP Right Cessation
- 1997-09-18 CA CA002266444A patent/CA2266444C/en not_active Expired - Fee Related
- 1997-09-22 ES ES97307379T patent/ES2180899T3/es not_active Expired - Lifetime
- 1997-09-22 ZA ZA978512A patent/ZA978512B/xx unknown
- 1997-09-22 EP EP97307379A patent/EP0831097B1/en not_active Expired - Lifetime
- 1997-09-22 SV SV1997000079A patent/SV1997000079A/es active IP Right Grant
- 1997-09-22 CO CO97055058A patent/CO4900057A1/es unknown
- 1997-09-22 DK DK97307379T patent/DK0831097T3/da active
- 1997-09-22 DE DE69714165T patent/DE69714165T2/de not_active Expired - Lifetime
- 1997-09-22 MY MYPI97004393A patent/MY125467A/en unknown
- 1997-09-22 SI SI9730408T patent/SI0831097T1/xx unknown
- 1997-09-22 AT AT97307379T patent/ATE221074T1/de active
- 1997-09-22 PT PT97307379T patent/PT831097E/pt unknown
- 1997-09-23 AR ARP970104361A patent/AR009801A1/es not_active Application Discontinuation
- 1997-09-23 PE PE1997000853A patent/PE110298A1/es not_active Application Discontinuation
- 1997-09-23 US US08/935,883 patent/US6251895B1/en not_active Expired - Fee Related
- 1997-09-23 EG EG98597A patent/EG23815A/xx active
-
1998
- 1998-02-27 TW TW086113833A patent/TW518335B/zh not_active IP Right Cessation
- 1998-09-21 HK HK98110803A patent/HK1009809A1/xx not_active IP Right Cessation
-
1999
- 1999-03-19 NO NO19991339A patent/NO323979B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE110298A1 (es) | Dihidrato d de olanzapina | |
IL113912A (en) | Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders | |
NO178766C (no) | Analogifremgangsmåte for fremstilling av benzodiazepin og mellomprodukter derav | |
BR9508751A (pt) | Composto formulação e processos de tratamento ou profilaxia de disfunções psicóticas ou disfunções de debilitação intelectual e da ansiedade e de preparação do composto | |
ID28432A (id) | Senyawa-senyawa baru | |
HK1046274A1 (en) | Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders. | |
MA24437A1 (fr) | Procede de la preparation et de la formulation de dihydrate d'eprosartan | |
BG106509A (en) | Preparative form | |
HUP0103636A2 (hu) | 2-Metil-tieno-benzodiazepin készítmény és alkalmazása | |
FR2770216B1 (fr) | Procede d'obtention de la forme polymorphe epsilon de l'hexanitrohexaazaisowurtzitane | |
HUP0002742A3 (en) | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
ID18260A (id) | Turunan 3-disubstitusi pirido (4',3':4,5) tieno (2,3-d) pirimidin, pembuatan dan penggunaan daripadanya | |
NO20013645L (no) | Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjon av de perifere benzodiazepinreseptorer | |
FR2744648B1 (fr) | Procede de preparation d'agents tensioactifs | |
BR9708595A (pt) | Utilização de derivados de 2,5- di-hidroxibenzenossulfonicos | |
HUP9904030A3 (en) | Use of tiagabine for production of pharmaceutical against psychotic disorders | |
HUP9903688A3 (en) | Use of olanzapine for the preparation of pharmaceutical compositions treating autism | |
HUP0002736A3 (en) | 3-substituted pyrido [3',4':4,5]thieno[2,3-d]pyrimidine derivatives, and their use for the preparation of pharmaceutical compositions | |
FR2804103B1 (fr) | Procede de conditionnement d'effluents de soude sous forme nepheline | |
AR018171A1 (es) | Compuestos de 2-metil-4-(4-metil-1-piperazinil)10 h-tieno [2,3-b] [1.5] benzodiazepina-olanzapina- como sal pamoato de la misma, solvatos de dicha sal y uso de los mismos para preparar composiciones para el tratamiento de animales, inclusive al hombre que padece psicosis, manias agudas o estados lev | |
ITMI931897A0 (it) | 1,3,4- benzotriazepin-554h)-one e procedimento per la loro preparazione | |
HUP9902882A2 (hu) | Olanzapin alkalmazása álmatlanság kezelésére szolgáló gyógyszerkészítmények előállítására | |
FR2736635B1 (fr) | Procede de preparation d'alpha,omega-bromochloroalcanes | |
NO984430D0 (no) | Anvendelse av en inhibitor av Na+/H+-utveksler for fremstilling av medikament for behandling av profylakser av sykdommer i sentralnervesystemet | |
ES1023676Y (es) | "sistema neumatico simulador de funciones fisiologicas para mu\ecos" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |